Internal Medicine, Pulmonary Disease · New Smyrna Beach, FL
NPI
1649277880
Since 2005
Specialty
Internal Medicine, Pulmonary Disease
Code 207RP1001X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
1055 N Dixie Fwy, Suite 1
New Smyrna Beach, FL, 32168
Phone (386) 423-0505
Groups this clinician bills Medicare through
Medicare paid, 2024
$852K
56,044 services
Medicare patients, 2024
2,104
Average age 76
Drug cost, 2024
$2.3M
12,433 prescriptions
Company payments, 2025
$2,700
From 24 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Rajesh K Ailani was code J1010 (injection, methylprednisolone acetate, 1 mg), 28,723 times for 255 patients. In total Rajesh K Ailani billed 56,044 services in 77 codes, and Medicare paid $852K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-05-09.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1010 Injection, methylprednisolone acetate, 1 mg | Office | 28,723 | 255 | $0.10 | $2,971 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 8,629 | 161 | $0.09 | $784 |
| 99214 Office E&M - Established | Office | 2,779 | 1,113 | $94.33 | $262K |
| 99233 Hospital E&M - Subsequent | Facility | 1,493 | 420 | $92.34 | $138K |
| J0696 Injection, ceftriaxone sodium, per 250 mg | Office | 1,295 | 84 | $0.36 | $466 |
| 94060 Pulmonary Function Testing | Office | 967 | 747 | $28.26 | $27K |
| 96365 Intravenous Infusion, Hydration | Office | 878 | 175 | $46.74 | $41K |
| 96375 Injection Administration | Office | 814 | 164 | $11.53 | $9,385 |
| 94729 Pulmonary Function Testing | Office | 713 | 681 | $41.56 | $30K |
| 94726 Pulmonary Function Testing | Office | 713 | 681 | $40.79 | $29K |
| J1956 Injection, levofloxacin, 250 mg | Office | 685 | 90 | $0.76 | $520 |
| 96372 Injection Administration | Office | 590 | 335 | $10.66 | $6,291 |
| 99232 Hospital E&M - Subsequent | Facility | 482 | 235 | $61.23 | $30K |
| 99291 Critical Care E&M | Facility | 268 | 72 | $167.15 | $45K |
| J1335 Injection, ertapenem sodium, 500 mg | Office | 218 | 34 | $8.79 | $1,917 |
By year: 2022 $764K for 31,513 services; 2023 $816K for 31,133 services; 2024 $852K for 56,044 services.
Lab tests billed to Medicare, 2022
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85610 Clinical Chemistry | 38 | 14 | $4.25 | $161 |
| 85018 Blood Count | 23 | 23 | $2.32 | $53.36 |
Medicare prescription drug claims, 2024
In 2024, the drug Rajesh K Ailani prescribed most often to Medicare patients was Prednisone, with 1,523 prescriptions and refills. In total Rajesh K Ailani wrote 12,433 Medicare prescriptions that cost $2.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Prednisone Generic | 1,523 | 1,766 | 675 | $8,770 |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | 1,099 | 1,468 | 253 | $866K |
| Montelukast Sodium Generic | 1,070 | 2,614 | 344 | $17K |
| Albuterol Sulfate Hfa Albuterol Sulfate | 812 | 1,029 | 279 | $23K |
| Cefdinir Generic | 600 | 600 | 373 | $9,973 |
| Ipratropium Bromide Generic | 598 | 1,045 | 269 | $15K |
| Levofloxacin Generic | 498 | 498 | 312 | $3,725 |
| Breo Ellipta Fluticasone/Vilanterol | 366 | 574 | 94 | $213K |
| Fluticasone-Salmeterol Fluticasone Propion/Salmeterol | 348 | 649 | 124 | $50K |
| Fluticasone Propionate Generic | 268 | 540 | 113 | $4,261 |
| Losartan Potassium Generic | 239 | 531 | 63 | $1,937 |
| Zolpidem Tartrate Generic | 182 | 234 | 36 | $1,743 |
| Furosemide Generic | 172 | 361 | 70 | $926 |
| Ventolin Hfa Albuterol Sulfate | 160 | 190 | 60 | $10K |
| Alprazolam Generic | 148 | 163 | 37 | $1,159 |
Brand drugs: 3,438 claims; generic drugs: 8,976 claims; opioid claims: 84.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Rajesh K Ailani $2,700 ($2,700 in general payments such as food, travel and fees) from 24 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $449.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 16 | $449 |
| GlaxoSmithKline, LLC. GSK | 38 | $417 |
| Jazz Pharmaceuticals Inc. JAZZ | 10 | $304 |
| Insmed, Inc. INSM | 12 | $186 |
| Grifols USA, LLC | 12 | $164 |
| Regeneron Healthcare Solutions, Inc. REGN | 7 | $154 |
| Amgen Inc. AMGN | 5 | $113 |
| Inspire Medical Systems, Inc. INSP | 2 | $110 |
| Abbvie Inc. ABBV | 5 | $108 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 3 | $105 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.